-
Chapter and Conference Paper
Combination of 5-FU, Leucovorin and Cisplatin (CDDP): an efficient low-toxic chemotherapy in advanced gastric adenocarcinoma
Metastatic gastric cancer remains a frequent disease with spontaneous median survival of about 6 months [1]. FAM regimen (5-FU, Doxorubicin and Mitomycin) was until the nineteens, considered as standard treatm...
-
Article
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer
Abstract
-
Article
Le point sur la prise en charge des cancers digestifs
-
Article
Le point sur les traitements adjuvants et néoadjuvants des adénocarcinomes œsogastriques
Malgréde récents progrés dans la prise en charge des adénocarcinomes œsogastriques (AOG), leur mortalitéreste élevée et leur traitement est encore un véritable challenge pour les oncologues. Le traitement chir...
-
Article
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases
To assess the rate of R0 resection of liver metastases achieved after chemotherapy with FOLFIRINOX.
-
Article
Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT
This study compared superparamagnetic iron-oxide-enhanced magnetic resonance imaging (SPIO-MRI) and combined fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) in evaluating l...
-
Article
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX
Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors.
-
Article
Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
Advances in the understanding of the mechanisms involved in oncogenesis have led to the development of so-called targeted therapies such as epidermal growth factor receptor (EGFR) inhibitors, which take on an ...
-
Article
Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm
Cutaneous adverse events induced by epidermal growth factor receptor (EGFR) inhibitors can hamper the patients' quality of life. The aim of our work was to draft an algorithm for the optimised management of th...